Abstract
Insulinoma is the most common neuroendocrine tumor of the pancreas. Surgical management of insulinomas is considered to be the only curative method. However, effective glycemic control preoperatively and in unresectable insulinomas remains a significant issue. Hyperinsulinism, occurring as a result of the hormone-secreting tumor, leads to life-threatening hypoglycemia episodes which require urgent medical treatment. This article discusses current management of hypoglycemia in insulinoma patients, including: education and lifestyle modifications, pharmacotherapy (diazoxide, somatostatin analogs, mTOR inhibitor — everolimus), cytoreductive methods and continuous glucose monitoring systems.
Article PDF
Similar content being viewed by others
References
de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA, 2011 New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 75: 277–284.
Ellison TA, Edil BH, 2012 The current management of pancreatic neuroendocrine tumors. Adv Surg 46: 283–296.
Okabayashi T, Shima Y, Sumiyoshi T, et al, 2013 Diagnosis and management of insulinoma. World J Gastroenterol 19: 829–837.
Cryer PE, Axelrod L, Grossman AB, et al, 2009 Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 94: 709–728.
Ito T, Igarashi H, Jensen RT, 2012 Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol 26: 737–753.
Davi MV, Pia A, Guarnotta V, et al, 2016 The treatment of hyperinsulinemic hypoglycaemia in adults: an update. J Endocrinol Invest 40: 9–20.
Desimone ME, Weinstock RS, 2016 Non-Diabetic Hypoglycemia. Endotext [Internet].
Baudin E, Caron P, Lombard-Bohas C, et al, 2013 Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris) 74: 523–533.
Jensen RT, Cadiot G, Brandi ML, et al, 2012 ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95: 98–119.
Tabarin A, Goichot B, 2013 Treatment: symptomatic treatment of hypoglycaemia. Ann Endocrinol (Paris) 74: 196–199.
Altszuler N, Moraru E, Hampshire J, 1977 On the mechanism of diazoxide-induced hyperglycemia. Diabetes 26: 931–935.
Proglycem — product monograph from Merck Canada Inc https://doi.org/www.merck.ca/assets/en/pdf/products/PRO-GLYCEM-PM_E.pdf
Oberg K, 2010 Pancreatic Endocrine Tumors. Semin Oncol 37: 594–618.
Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA, 1986 Diazoxide in the management of patients with insulinoma. World J Surg 10: 586–592.
Gill GV, Rauf O, MacFarlane IA, 1997 Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 73: 640–641.
Ferrer-García JC, Iranzo González-Cruz V, Navas-DeSolís S, et al, 2013 Management of malignant insulinoma. Clin Transl Oncol 15: 725–731.
Hirshberg B, Cochran C, Skarulis MC et al, 2005 Malignant insulinoma: spectrum of unusual clinical features. Cancer 104: 264–272.
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ, 1996 Octreotide. N Engl J Med 334: 246–254.
Oberg K, Kvols L, Caplin M, et al, 2004 Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15: 966–973.
Ito T, Hijioka S, Masui T, et al, 2016 Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol 52: 9–18.
Wild D, Christ E, Caplin ME, et al, 2011 Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 52: 1073–1078.
Iglesias P, Diez JJ, 2014 Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol 170: R147–157.
The Conversion of Short Acting Octreotide to Long Acting Lanreotide. Retrieved 07.11.2016 from https://doi.org/olh.ie/wp-content/uploads/2014/09/The-Conversion-of-Short-Acting-Octreotide-to-Long-Acting-Lanreotide.pdf
Oberg K, Ferone D, Kaltsas G, et al, 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuro endocrinology 90: 209–213.
Oberg K, Eriksson B, 2005 Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19: 753–781.
Tirosh A, Stemmer SM, Solomonov E, et al, 2016 Pasireotide for malignant insulinoma. Hormones (Athens) 15: 271–276.
Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G, 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146: 707–716.
Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET, 2007 Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas — predominance of receptor subtype 4. Endocr Pathol 18: 79–85.
Yao JC, Lombard-Bohas C, Baudin E, et al, 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28: 69–76.
FDA Approval for everolimus. https://doi.org/www.cancer.gov/about-cancer/treatment/drugs/fda-everolimus
Yao JC, Shah MH, Ito T, et al, 2011 RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514–523.
Bernard V, Lombard-Bohas C, Taquet MC, et al, 2013 Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol 168: 665–674.
Fiebrich HB, Siemerink EJ, Brouwers AH, et al, 2011 Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist 16: 783–787.
Asayama M, Yamada-Murano T, Hara H, et al, 2014 Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report. Jpn J Clin Oncol 44: 186–190.
Baratelli C, Brizzi MP, Tampellini M, et al, 2014 Intermittent everolimus administration for malignant insulinoma. Endocrinol Diabetes Metab Case Rep 2014: 140047.
Kulke MH, Bergsland EK, Yao JC, 2009 Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360: 195–197.
Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG, 2010 Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 162: 1001–1008.
Bozkirli E, Bakiner O, Abali H et al, 2013 A Case of Inoperable Malignant Insulinoma with Resistant Hypoglycemia Who Experienced the Most Significant Clinical Improvement with Everolimus. Case Rep Endocrinol 2013: 636175.
Ferrer-García JC, Tolosa-Torréns M, Hernando-Meliá C, Arribas-Palomar L, Sánchez-Juan C, 2011 Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocr Pract 17: e17–20.
Nahmias A, Grozinsky-Glasberg S, Salmon A, Gross DJ, 2015 Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease. Endocrinol Diabetes Metab Case Rep 2015: 150032.
Dubey AP, Viswanath S, 2016 A case of metastatic insulinoma: Management and review of literature. OGH Reports 5: 79–81.
Le Bacquer O, Queniat G, Gmyr V, Kerr-Conte J, Lefebvre B, Pattou F, 2013 mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells. J Endocrinol 216: 21–29.
Houde VP, Brûlé S, Festuccia WT, et al, 2010 Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59: 1338–1348.
Novotny J, Janku F, Mares P, Petruzelka L, 2005 Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer 13: 760–762.
Kulaksızoglu M, Gonen MS, Kebapcilar L, et al, 2013 Treatment of recurrent hypoglycemia with plasmapheresis and steroid in nondiabetic patient. Transfus Apher Sci 48: 11–13.
Service FJ, 2006 Recurrent hyperinsulinemic hypoglycemia caused by an insulin-secreting insulinoma. Nat Clin Pract Endocrinol Metab 2: 467–470.
Blum I, Rusecki Y, Doron M, et al, 1983 Evidence for a therapeutic effect of dl-propranolol in benign and malignant insulinoma: report of three cases. J Endocrinol Invest 6: 41–45.
Blum I, Doron M, Laron Z, Atsmon A, Tiqva P, 1975 Prevention of hypoglycemic attacks by propranolol in a patient suffering from insulinoma. Diabetes 24: 535–537.
Scandellari C, Zaccaria M, De Palo C, et al, 1978 The effect of propranolol on hypoglycaemia. Observations in five insulinoma patients. Diabetologia 15: 297–301.
Imanaka S, Matsuda S, Ito K, Matsuoka T, Okada Y, 1986 Medical treatment for inoperable insulinoma: clinical usefulness of diphenylhydantoin and diltiazem. Jpn J Clin Oncol 16: 65–71.
Brodows RG, Campbell RG, 1974 Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin. J Clin Endocrinol Metab 38: 159–162.
Hofeldt FD, Dippe SE, Levin SR, et al, 1974 Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma. Diabetes 23: 192–198.
Owecki M, Sowiński J, 2005 Successful pharmacological treatment of hyperinsulinemic hypoglycemia with verapamil and amlodipine-case report. Pol Merkur Lekarski 19: 196–198.
Ulbrecht JS, Schmeltz R, Aarons JH, Greene DA, 1986 Insulinoma in a 94-year-old woman: long-term therapy with verapamil. Diabetes Care 9: 186–188.
Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, 1989 Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201–995) more effective than single therapy with either drug? Neth J Med 35: 86–94.
Hanazaki K, Nosé Y, Brunicardi FC, 2001 Artificial endocrine pancreas. J Am Coll Surg 193: 310–322.
Hirose K, Kawahito S, Mita N, et al, 2014 Usefulness of artificial endocrine pancreas during resection of insulinoma. J Med Invest 61: 421–425.
Munir, A, Choudhary P, Harrison B, Heller S, Newell-Price J, 2008 Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol (Oxf) 68: 912–918.
Tong CV, Hussein Z, Mohamad MB, Noor NM, Nasruddin A, 2015 Continuous Glucose Monitoring (CGM) — a Useful Tool in Tailoring Treatment for Insulinoma. Endocr Rev 36: LBS–056.
Baldeweg SE, Hope S, Tibbals J, Davidson B, Vanderpump M, 2003 Use of Continous glucose monitoring system in the medical management of insulinomas. Endocrine Abstracts 6: DP23.
Lombardi M, De Lio N, Funel N, et al, 2015 Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET. J Endocrinol Investig 38: 605–613.
Oberg K, 2012 Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol 26: 833–841.
Venook AP, 1999 Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 11: 38–41.
Logan R. McKenna, Barish H. Edil, 2014 Update on pancreatic neuroendocrine tumors. Gland Surg 3: 258–275.
Paprottka PM, Hoffmann RT, Haug A, et al, 2012 Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35: 334–342.
Falconi M, Eriksson B, Kaltsas G, et al, 2016 ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 103: 153–171.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Matej, A., Bujwid, H. & Wroński, J. Glycemic control in patients with insulinoma. Hormones 15, 489–499 (2016). https://doi.org/10.14310/horm.2002.1706
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1706